NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer
NEO100’s survival findings come from an uncontrolled study, while a separate NEO212 program has a confirmed FDA meeting.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeOnc Technologies Holdings (NTHI) reported median overall survival of 26.09 months in its Phase 2a study of intranasal NEO100 for recurrent brain cancer. The 24-patient study enrolled people with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. Survival was measured from the first treatment dose after recurrence; estimated survival was 60.9% at 12 months and 54.1% at 24 months. Adverse events were predominantly low-grade, with no major toxicities reported.
The study had no concurrent control group. Progression-free survival reached statistical significance against a historical benchmark under RANO 2.0 assessment criteria, but not under the original protocol criteria. NeOnc plans FDA discussions on a registrational pathway. Separately, an FDA End-of-Phase 1 meeting for NEO212 is confirmed for November 17, 2026; it does not establish an agreed approval pathway.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointMedian overall survival of 26.09 months observed in the 24-patient NEO100 Phase 2a study, measured from treatment after recurrence.
- Moderate point. Forward-looking: it has not happened yet and may not happen.NEO100 development: NeOnc plans FDA discussions on a registrational pathway.
- Moderate pointNEO212 FDA End-of-Phase 1 meeting confirmed for November 17, 2026, covering proposed development and potential marketing-application evidence.
- Minor pointEstimated survival was 60.9% at 12 months and 54.1% at 24 months in the NEO100 cohort.
- Minor pointPredominantly low-grade adverse events and no major toxicities reported in the NEO100 cohort.
Negative
- Moderate pointNo concurrent control group means NEO100’s survival findings are not a randomized demonstration of improved survival.
- Moderate pointProgression-free survival was statistically significant against the historical benchmark under RANO 2.0, but not original protocol criteria.
- Minor pointNEO212’s confirmed FDA meeting does not itself establish an agreed approval pathway.
Key Figures
- Study sample size
- 24 patients
- NEO100 Phase 2a study
- Median overall survival
- 26.09 months
- NEO100 Phase 2a study; measured from first treatment dose following recurrence
- Estimated survival
- 60.9%
- At 12 months in the NEO100 study
- Estimated survival
- 54.1%
- At 24 months in the NEO100 study
- FDA meeting date
- November 17, 2026
- NEO212 End-of-Phase 1 meeting; separate from NEO100
Historical Context
-
Reported NEO100 Phase 2a survival of 26.09 months and six-month progression-free survival of 48.9%.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
median overall survival medical
blood-brain barrier medical
phase 2a medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NeOnc’s encouraging brain-cancer survival findings join developments from Revolution Medicines, Moderna and Merck, Johnson & Johnson, and Genmab and AbbVie.
DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com)-- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time?
A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These developments span different levels of clinical evidence, from exploratory Phase 2 findings to randomized Phase 3 results and an FDA approval. SEC
24/7 Market News highlights five advances worth following as the year moves into its final quarter, beginning with NeOnc Technologies Holdings and its work in a particularly difficult treatment setting: aggressive brain cancer that has returned after previous therapy.
NeOnc Technologies Holdings (NASDAQ: NTHI): Encouraging Survival Findings Where Better Options Are Urgently Needed
NeOnc stands out in this group for the challenge it is confronting. Recurrent high-grade brain cancer remains an exceptionally difficult treatment setting. The National Cancer Institute notes that recurrent central nervous system tumors are rarely curable, underscoring the importance of developing additional treatment options. Cancer.gov
On August 12, NeOnc reported that patients in its 24-patient Phase 2a study of intranasal NEO100 achieved a median overall survival of 26.09 months. Estimated survival was
The treatment approach is also distinctive. NEO100 is administered intranasally by patients at home and is designed to reach the brain through pathways that bypass the blood-brain barrier, a major obstacle in brain-cancer drug delivery. NeOnc reported predominantly low-grade adverse events and no major toxicities in the cohort. SEC
These findings represent an encouraging survival signal, not a randomized demonstration of improved survival. The study had no concurrent control group, and progression-free-survival findings varied by assessment method, reaching statistical significance against the historical benchmark under RANO 2.0 but not under the original protocol-specified criteria. NeOnc has outlined plans to discuss a registrational development pathway with the FDA. SEC
For a disease setting where treatment options are limited, the combination of observed survival, reported tolerability and an at-home delivery approach makes NEO100 a development worth following as further clinical evaluation proceeds. Cancer.gov
Revolution Medicines (NASDAQ): A Pancreatic-Cancer Advance That Has Already Reached Approval
Revolution Medicines delivered one of the year’s clearest examples of clinical progress translating into an available treatment. On August 26, the FDA approved Rasonque, or daraxonrasib, a targeted therapy for metastatic pancreatic adenocarcinoma. Revolution Medicines
In a randomized study involving 500 previously treated patients, median overall survival reached 13.2 months with Rasonque versus 6.7 months with standard chemotherapy. Unlike an uncontrolled survival observation, this result established a benefit against a treatment comparator within the same trial. U.S. Food and Drug Administration
The approval is particularly meaningful in pancreatic cancer, where aggressive disease, late detection and historically limited treatment options have contributed to poor outcomes. It also provides a concrete example of what successful clinical development can accomplish: moving a promising approach from research into patient care. U.S. Food and Drug Administration
Moderna (NASDAQ) and Merck (NYSE): Personalized Cancer Immunotherapy Reaches a Phase 3 Milestone
Moderna and Merck reported a different kind of advance on August 19: positive Phase 3 results for intismeran autogene, an individualized mRNA-based cancer therapy, combined with Keytruda.
The INTerpath-001 trial demonstrated statistically significant improvements in recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone in patients whose high-risk melanoma had been surgically removed. According to the companies, this was the first positive Phase 3 result for an individualized neoantigen therapy and an mRNA-based cancer treatment. Merck.com
The approach is designed around the characteristics of an individual patient’s tumor. Its promise is not a universal vaccine against cancer, but a more personalized immune response to the disease. Overall-survival follow-up continues, while the companies plan to engage regulators regarding potential submissions. Merck.com
Johnson & Johnson (NYSE): Dual-Target Immunotherapy Delivers Substantial Myeloma Results
On July 23, Johnson & Johnson reported that combining Tecvayli and Talvey in the Phase 3 MonumenTAL-6 trial reduced the relative risk of disease progression or death by
The trial involved patients with relapsed or refractory multiple myeloma who had received one to four prior treatment lines. The combination targets two different proteins associated with myeloma cells, BCMA and GPRC5D, directing immune activity against the disease through complementary targets. JNJ.com
The investigational combination’s improvements in both disease control and overall survival support the potential to bring this dual-target approach earlier into treatment. The reported percentages describe relative reductions in risk, not percentages of patients cured. JNJ.com
Genmab (NASDAQ) and AbbVie (NYSE): New Hope in First-Line Aggressive Lymphoma
On October 5, Genmab and AbbVie announced that adding epcoritamab to the standard R-CHOP regimen reduced the relative risk of progression or death by
The reported result applied to newly diagnosed diffuse large B-cell lymphoma patients with International Prognostic Index scores of 2–5. Its importance lies in the possibility of improving treatment at the outset, rather than waiting until the disease returns. AbbVie News Center
The combination remains investigational. The companies plan regulatory discussions and presentation of the findings at a future medical meeting, making this another development to follow beyond its initial announcement. AbbVie News Center
Taken together, these developments offer reasons for optimism without suggesting that every clinical question has been answered. An approved therapy, positive randomized trials and an early survival signal occupy different positions along the development path. Their shared importance is the effort to improve outcomes where existing treatments remain insufficient.
For NeOnc, the coming months also include a confirmed November 17, 2026, FDA End-of-Phase 1 meeting for its separate NEO212 program, covering proposed clinical-development plans and the evidence needed for a potential future marketing application. That meeting is distinct from NEO100’s development discussions and does not itself establish an agreed approval pathway. SEC
The hopeful turn in 2026 is not that cancer has been solved. It is that several approaches are producing evidence worth advancing and, in some cases, treatments patients can already receive.
For patients and families, the ultimate significance is not a company’s size or stock symbol. It is the possibility of more birthdays, more ordinary days, and more time together.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What survival results did NeOnc report for NEO100 in recurrent brain cancer?
NeOnc reported median overall survival of 26.09 months in a 24-patient Phase 2a study. Estimated survival was 60.9% at 12 months and 54.1% at 24 months, measured from the first treatment dose following recurrence rather than original diagnosis. The study had no concurrent control group.
When is NeOnc’s NEO212 FDA meeting, and what will it cover?
The NEO212 FDA End-of-Phase 1 meeting is confirmed for November 17, 2026. It will cover proposed clinical-development plans and evidence needed for a potential future marketing application. It is separate from NEO100 development discussions and does not itself establish an agreed approval pathway.
How is NeOnc’s NEO100 administered?
Patients administer NEO100 intranasally at home. NeOnc describes the approach as designed to reach the brain through pathways that bypass the blood-brain barrier, an obstacle to delivering drugs to the brain.